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Objectives: The primary aim of the RELIEF study was to evaluate the efﬁcacy and safety of two sequential
intravenous (iv)/oral regimens: moxiﬂoxacin iv/oral versus piperacillin/tazobactam (TZP) iv followed by oral
amoxicillin/clavulanate (AMC).
Patients and methods: The study had a prospective, randomized, double-dummy, double-blind, multicentre
design. Patients ≥18 years were prospectively stratiﬁed according to complicated skin and skin structure infec-
tion (cSSSI) subtype/diagnosis (major abscess, diabetic foot infection, wound infection or infected ischaemic
ulcer), surgical intervention and severity of illness. Diagnoses and disease severity were based on predeter-
mined criteria, documented by repeated photographs, and conﬁrmed by an independent data review commit-
tee. Patients were randomized to receive either 400 mg of moxiﬂoxacin iv once daily followed by 400 mg of
moxiﬂoxacin orally once daily or 4.0/0.5 g of TZP iv thrice daily followed by 875/125 mg of AMC orally twice
daily for 7–21 days. The primary efﬁcacy variable was clinical response at test of cure (TOC) for the per-protocol
(PP) population. Clinical efﬁcacy was assessed by the data review committee based on repeated photographs
and case descriptions. Clinical trials registry number: NCT 00402727.
Results: A total of 813 patients were randomized. Clinical success rates at TOC were similar for moxiﬂoxacin and
TZP–AMC in the PP [320/361 (88.6%) versus 275/307 (89.6%), respectively; P¼0.758] and intent-to-treat (ITT)
[350/426 (82.2%) versus 305/377 (80.9%), respectively; P¼0.632] populations. Thus, moxiﬂoxacin was non-
inferior to TZP–AMC. Bacteriological success rates were high in both treatment arms [moxiﬂoxacin: 432/497
(86.9%) versus TZP–AMC: 370/429 (86.2%), microbiologically valid (MBV) population]. Moxiﬂoxacin was non-
inferior to TZP–AMC at TOC in both the MBV and the ITT populations. Both treatments were well tolerated.
Conclusions: Once-daily iv/oral moxiﬂoxacin monotherapy was clinically and bacteriologically non-inferior to iv
TZP thrice daily followed by oral AMC twice daily in patients with cSSSIs.
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Introduction
Skin and skin structure infections (SSSIs)
1 may require hospitaliz-
ation, especially among high-risk populations,
2 and are a
common indication for intravenous (iv) antibiotic use.
3 SSSIs
are considered complicated (cSSSIs) when they involve deeper
soft tissue (fascia and/or muscle layers), require signiﬁcant surgi-
cal intervention or occur in patients with a co-morbid condition
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2632that may compromise the response to treatment (e.g. dia-
betes).
1,4 cSSSIs lead to signiﬁcant morbidity and mortality,
and impact considerably on healthcare resource utilization.
5
cSSSIs are caused by Gram-positive and Gram-negative
aerobic and anaerobic pathogens; the latter are more frequently
associated with severe infections in the anogenital area or lower
half of the body.
3,6 Many different pathogens, alone or as part of
a polymicrobial infection, are involved in cSSSIs, and will vary
depending on the clinical situation, location of the infection
and medical history of the patient.
1 The management of
cSSSIs normally involves both surgical debridement and empiri-
cal antibiotic therapy.
Moxiﬂoxacin has an extended spectrum of activity
against Gram-positive cocci, including methicillin-susceptible
Staphylococcus aureus, and aerobic and anaerobic bacteria, and
signiﬁcant activity against many Gram-negative bacteria.
7–11 It
is active against non-growing Escherichia coli and Bacteroides fra-
gilis in experimental abscesses,
12 and its in vitro activity against S.
aureus and E. coli is not reduced in an anaerobic milieu.
13 It is not,
however, recommended against methicillin-resistant S. aureus
(MRSA). Moxiﬂoxacin has good tissue penetration
14,15 and iv to
oral switch-down is simple, as the pharmacokinetic proﬁles for
the two formulations are virtually interchangeable.
16,17 Its once-
daily formulation makes it a convenient antimicrobial option.
These properties, combined with proven efﬁcacy and tolerability
versus b-lactam/b-lactamase inhibitors, make moxiﬂoxacin a
valuable treatment option, including in patients in whom
b-lactams are contraindicated.
3,18 While previous studies of iv/
oral moxiﬂoxacin in cSSSIs show it to be effective and well toler-
ated, they were limited by a lack of stratiﬁcation with respect to
infection severity and the requirement for baseline surgery.
This common omission from cSSSI trials is addressed in the
RELIEF study.
Patients and methods
Study design
This prospective, randomized, double-dummy, double-blind study (clini-
cal trials registry number: NCT 00402727; http://clinicaltrials.gov/ct2/
show/NCT00402727) was carried out from September 2006 to June
2008 in 61 centres worldwide (Belgium, Bulgaria, Germany, Greece,
Hungary, Israel, Latvia, Lithuania, Poland, Romania, Russia, South
Africa, Spain, Ukraine and the UK). Documented approval for the study
was obtained from the Ethics Committee for all participating centres
and written informed consent was sought from all participants. The
study was carried out under Good Clinical Practice guidelines and in
accordance with the Declaration of Helsinki. Dr Inge Gyssens had full
access to the study data and is the guarantor of the data.
Deﬁnitions and diagnosis of cSSSI
A cSSSI was deﬁned as a bacterial SSSI that required hospitalization,
initial parenteral therapy for ≥48 h and which met at least one of the fol-
lowing criteria: deep soft tissue involvement; requirement for signiﬁcant
surgical intervention, including surgical drainage and/or debridement;
and association with a complicating co-morbid condition. Prior to ran-
domization, patients were stratiﬁed by the local investigator according
to the type of infection [major abscess, diabetic foot infection (DFI),
wound infection or infected ischaemic ulcer], requirement for surgical
intervention and Wilson risk class.
19 Major abscesses were deﬁned as
pus collection being associated with extensive cellulitis, and required
antibiotic therapy in addition to surgical incision and drainage. DFIs
were infections occurring below the ankle in patients with conﬁrmed
diabetes. DFIs were characterized, and their severity graded using the
PEDIS (perfusion, extent/size, depth/tissue loss, infection and sensation),
Wagner and University of Texas Wound classiﬁcation systems.
20–23
Wound infections included post-surgical (surgical incision), post-
traumatic, human bite/clenched ﬁst and animal bite wounds, and
wounds associated with injection drug abuse. Infected ischaemic
ulcers were deﬁned as occurring in patients with peripheral vascular
disease. The diagnosis of cSSSI was validated by a blinded independent
data review committee (DRC) for all patients randomized in the study.
Patients with an infection that had not been conﬁrmed as a major
abscess, a DFI, an infected ischaemic ulcer or a wound infection by the
DRC were excluded from the primary efﬁcacy analysis.
Patients
Men and women (≥18 years old) with a cSSSI of ,21 days’ duration and
at least three of the following signs and symptoms were included: purulent
drainage or discharge; erythema extending .1 cm from the wound edge;
ﬂuctuance, pain or tenderness to palpation; swelling or induration; fever;
elevated total peripheral white blood cell (WBC) count .12000/mm
3
or .15% immature neutrophils regardless of total peripheral WBC; or
C-reactive protein .20 mg/L. For all patients, a tissue or ﬂuid specimen
was obtained from the infected area for culture. Swabs were not
accepted. Exclusion criteria included: necrotizing fasciitis; burn wound
infections; secondary infections of a chronic skin disease; infection of a
prosthesis; infections where a surgical procedure alone was deﬁnitive
therapy, such as amputation through a clean site and after abscess
drainage without extensive cellulitis or an uncomplicated SSSI (uSSSI);
contraindications to any of the study drugs; a life expectancy
,2 months; severe hepatic insufﬁciency (Child–Pugh C); or transamin-
ases above ﬁve times the upper limit of normal or creatinine clearance
,40 mL/min. Women who were lactating or pregnant were also
excluded, as were patients with neutropenia, lymphocytopenia, an AIDS-
deﬁning event, antiretroviral therapy and chronic immunosuppressant
therapy. Other exclusion criteria included antibacterial treatment for
.24 h in the 7 days preceding study entry, unless the patient showed
no response or had worsening of clinical signs and symptoms despite
treatment for ≥3 days and a culture before enrolment showed
persistence of a pathogen that was susceptible to the study drugs.
Patients with an infection known to be due to MRSA, methicillin-resistant
Staphylococcus epidermidis or vancomycin-resistant enterococci as the
single pathogen were also excluded.
Surgical treatment
Patients had to receive a surgical intervention within 48 h of initiation of
the study drug to qualify as having undergone baseline surgery.
Drug treatments
The randomization code was generated by the Department of Biometry
at Bayer Healthcare AG. Eligible patients were randomly assigned in a
1:1 ratio to one of two treatment groups: moxiﬂoxacin (Group 1) or piper-
acillin/tazobactam–amoxicillin/clavulanate (TZP–AMC; Group 2) using an
interactive voice-response system. The sequence of the iv study drug
administration was also randomized. Treatment groups were subdivided
so that half of the patients received active treatment followed by placebo
and half received the same treatment but in the opposite order (placebo
followed by active treatment). Group 1 received 400 mg of moxiﬂoxacin
iv once daily and TZP placebo iv thrice daily, followed by 400 mg of
oral moxiﬂoxacin and oral AMC placebo twice daily. Group 2 received
4.0/0.5 g of piperacillin/tazobactam iv thrice daily and moxiﬂoxacin
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JACplacebo iv once daily, followed by 875/125 mg of oral amoxicillin/clavu-
lanate twice daily and oral moxiﬂoxacin placebo once daily. The decision
to switch from iv to oral therapy was made by the investigator, but the
patient had to have been afebrile for ≥24 h and received iv therapy for
≥3 days. The total treatment duration was 7–21 days. Blinding of the
patients, investigators and contract research personnel was maintained
throughout the study. Patients with a polymicrobial infection that
included culture-conﬁrmed MRSA, methicillin-resistant S. epidermidis or
vancomycin-resistant enterococci could be treated with additional
narrow-spectrum antibiotics.
Assessments
Clinical assessments were performed pre-treatment, during treatment
(days 3–5), at end of treatment (EOT) (days 7–21) and at test of cure
(TOC) (14–28 days post-therapy). At TOC, the clinical response was
graded as cure, failure or indeterminate. Cure was the disappearance
of acute signs and symptoms related to the infection or sufﬁcient
improvement, such that additional or alternative antimicrobial therapy
was not required. Failure was insufﬁcient lessening of the signs and
symptoms of infection, such that additional or alternative antimicrobial
therapy was required, or there was requirement for surgical intervention
to treat a persistent infection or development of another wound infection
at the original site of infection. Indeterminate was used for patients in
whom a clinical assessment could not be determined. Clinical success
was deﬁned as cure at TOC for patients not classiﬁed as clinical failure
at any evaluation visit earlier than TOC. The skin lesions of all patients
were photographed panoramically, and from the front and side (to deter-
mine the precise location of the lesion) at entry (repeated prior to any
surgery), on days 3–5, EOT, TOC and post-alternative therapy (if adminis-
tered). Patients with a DFI had the affected extremities radiographed to
assess for the presence of foreign materials, tissue gas or signs of osteo-
myelitis. Bacteriological assessment was carried out on pre-treatment
samples (wound and blood) and samples collected during the study.
Samples were collected via biopsy, curettage of the wound base after
debridement, tissue or bone biopsy, aspiration of purulent secretions,
or a leading-edge needle aspiration for patients with cellulitis. Samples
were inoculated directly into preservative medium (BBL Port-A-Cul Trans-
port vial or jar, Becton, Dickinson and Company, NJ, USA) and shipped
within 72 h to the central laboratory [Euroﬁns medinet SAS (formerly
Focus Bio-Inova Europe SAS), Plaisir cedex, France] for testing according
to CLSI guidelines. MICs were determined using validated reference
broth microdilution panels, and extended-spectrum b-lactamase activity
was determined for Enterobacteriaceae species using a standardized
method. Organisms were deﬁned as ‘pathogenic’ based on blinded post-
study evaluation. Common cSSSI pathogens, such as S. aureus and E. coli,
were always considered pathogenic. Other bacteria (e.g. Aerococcus
viridans) were never classiﬁed as a pathogen. Some species (e.g. Entero-
bacter cloacae or Enterococcus faecalis) were classiﬁed as a pathogen if
certain semi-quantitative growth requirements or clinical signs were
met. Bacteriological response was classiﬁed as: success (eradication or
presumed eradication); failure (persistence, presumed persistence, recur-
rence, reinfection or superinfection); or indeterminate. Colonization was
deﬁned as the isolation of a new organism (colonizer) that did not
require subsequent antimicrobial therapy. Safety assessments were
based on physical examination, vital signs, pre-treatment and on-therapy
electrocardiograms, adverse events (AEs), and standard laboratory tests.
For all patients with an AE meeting the deﬁnition of diarrhoea, a stool
sample was submitted to the central laboratory for Clostridium difﬁcile
toxin detection.
Study endpoints/variables
The primaryefﬁcacyendpoint wasthe clinical response determined bythe
DRC at TOC, i.e. 14–28 days after the last dose of the study drug. The DRC
was blinded to the country and site, treatment allocation, and local inves-
tigator for the evaluation of efﬁcacy. Members of the DRC received all
patient data that were part of the studydatabase for review. This included
clinical signs and symptoms at each assessment visit, concomitant medi-
cations, microbiology results, laboratory tests, and photographs. Photo-
graphs were interpreted by a central photograph-reading contract
research organization (Radpharm Inc., Princeton, NJ, USA). Patient data
were reviewed independently by at least three out of ﬁve members of
the DRC, where possible while the study was ongoing. Where there was
no initial agreement on diagnosis and/or clinical response or data queries
were raised, proﬁles and photographs were reviewed and discussed by
the complete DRC until consensus was reached. A secondaryefﬁcacy vari-
able was bacteriological response at days 3–5, EOTand TOC.
Populations for analysis
The patient populations for analysis were the safety/intent-to-treat (ITT)
population (all randomized patients receiving at least one dose of study
drug and having at least one observation), the per-protocol (PP) popu-
lation (ITT patients with fully documented cSSSI diagnostic criteria, no
protocol violations inﬂuencing outcome, no essential data missing and
no other systemic/topical antimicrobial agent administered concomi-
tantly during treatment unless the patient was a treatment failure)
and the microbiologically valid (MBV) population (PP patients with base-
line pathogens and a microbiological evaluation at TOC).
Statistical methods
Statistical analyses were adjusted for cSSSI subtype, severity of illness
and surgical procedure. Fourteen strata (based on subtype, risk class
and requirement for baseline surgery) were used for the analysis, but
the study was not powered to look at differences in the clinical efﬁcacy
between subgroups. Mantel–Haenszel point estimates and 95% conﬁ-
dence intervals (CIs) for the differences in clinical success rates at TOC
were used to compare the treatment groups (moxiﬂoxacin group
minus comparator group). The 95% CIs were calculated using Mantel–
Haenszel weights based on the 14 strata deﬁned. If the lower limit of
this CI exceeded 210%, it was shown that moxiﬂoxacin was clinically
not less effective than the comparator regimen. If the lower limit of
the CI exceeded 0, superiority of treatment with moxiﬂoxacin was
proven. The study was powered to demonstrate non-inferiority with
respect to clinical cure, as assessed by the DRC for the PP population
with supportive results in the ITT population.
AEs were classiﬁed according to the MedDRA code. Vital signs and
laboratory data were analysed descriptively.
Sample size estimation was based on the primary efﬁcacy variable
(clinical response at TOC visit) and the following assumptions: a true
failure rate of 20% in the control group; an equivalence (clinically rel-
evant) d¼10%; a¼5% (two sided); and b¼5%. This yielded a sample
size estimate of 321 valid patients per treatment group, including an
adjustment of 10% to account for the multicentre design of the study.
Assuming a validity rate of 80%, 402 patients were needed in each treat-
ment group.
Results
The ﬁrst patient was enrolled in September 2006 and the last
follow-up visit occurred in June 2008. The trial ended when the
required patient sample size (n¼402) was reached. Patient
ﬂow through the study is shown in Figure 1. Patients were gen-
erally well matched in terms of demographics and other charac-
teristics (Tables 1 and 2); although, in the PP population, WBC
and glycosylated haemoglobin (HbA1c) values were higher in
Gyssens et al.
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At baseline, cSSSI and disease-related characteristics were also
well matched between groups (Table 2). A majority of patients
with an abscess had systemic signs of infection (elevated WBC
and/or C-reactive protein) and were febrile (mean temperature
of 39.28C). Abscesses frequently involved deep tissues or had
complicated factors. Approximately 42% of valid PP patients
with abscesses had involvement of the underlying fat tissue
and a further 58% of patients had extension of the abscess to
the underlying fascia or muscle. Lesions were either major
abscesses, as evidenced by the mean size of the lesions
(112 cm
2), or carried a high risk of an anaerobic or Gram-
negative involvement; the majority of such abscesses were in
the genital or perianal regions. Approximately 80% of valid PP
patients had surgical procedures performed within 48 h of
initiation of study drug. Drainage, extensive or local debridement
and amputations were the most frequent interventions. Most
patients with an amputation were DFI patients, who had periph-
eral vascular disease, as evidenced by lower ankle-brachial
indices (data not shown). In these patients, adequate debride-
ment may require amputation at some level as a means of
removing non-viable infected tissue, including bone.
Enrolled (n=834)
Moxiﬂoxacin (n=432)
PP population (n=307)
Reasons for exclusion from PP population
￿ Violation of inclusion/exclusion criteria (n=34)
￿ Insufﬁcient duration of therapy (n=12)
￿ Violation of time schedule (n=3)
￿ Essential data missing/invalid (n=39)
￿ Use of prohibited pre-treatment medication (n=1)
￿ Organisms resistant to study drug (n=0)
￿ Use of prohibited concomitant medication (n=7)
￿ Use of prohibited post-treatment medication (n=4)
￿ Informed consent withdrawn (n=4)
￿ Lost to follow-up (n=4)
￿ Insufﬁcient surgical procedure (n=1)
MBV population (n=268) MBV population (n=243)
PP population (n=361)
Reasons for exclusion from PP population
￿ Violation of inclusion/exclusion criteria (n=34)
￿ Insufﬁcient duration of therapy (n=7)
￿ Violation of time schedule (n=3)
￿ Essential data missing/invalid (n=31)
￿ Use of prohibited pre-treatment medication (n=2)
￿ Organisms resistant to study drug (n=1)
￿ Use of prohibited concomitant medication (n=7)
￿ Use of prohibited post-treatment medication (n=4)
￿ Informed consent withdrawn (n=0)
￿ Lost to follow-up (n=4)
￿ Insufﬁcient surgical procedure (n=0)
Safety/ITT population (n=426)
Reasons for exclusion from ITT population
￿ Not treated with study drug (n=6)
Safety/ITT population (n=377)
Reasons for exclusion from ITT population
￿ Not treated with study drug (n=4)
Randomized (n= 813)
Consent withdrawn (n=11)
Protocol violation (n=10)
TZP–AMC (n=381)
Figure 1. Patient ﬂow through the study.
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No major difference was seen between treatment groups regard-
ing the frequency or type of baseline pathogens in the MBV popu-
lation (Table 3). A total of 497 pathogens were isolated from 268
moxiﬂoxacin-treated patients and 429 pathogens from 243
comparator-treated patients. In the moxiﬂoxacin arm, 129
(48.1%) patients had monomicrobial infections while 139
(51.9%) had polymicrobial infections. Corresponding numbers
in the comparator arm were 132 (54.3%) and 111 (45.7%),
respectively. Aerobic Gram-positive cocci were the most frequent
pathogens, were isolated in 65% of patients and included mainly
S. aureus (43%), b-haemolytic streptococci group A–G (20%) and
E. faecalis (16%), followed by aerobic Gram-negative bacilli
(mainly E. coli). MRSA was isolated from 23 MBV patients in the
moxiﬂoxacin arm and 15 MBV patients in the TZP–AMC arm; in
8/23 moxiﬂoxacin patients and 6/15 TZP–AMC patients, MRSA
was isolated as the sole pathogen at inclusion. Most
MBV patients with an MRSA isolate were from Eastern Europe
or the Russian Federation [n¼32/38 (84.2%)]. Overall, in the
moxiﬂoxacin arm, 1/5/18 MRSA isolates were susceptible/
intermediate/resistant to moxiﬂoxacin using European Commit-
tee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints
(≤0.5/1/.1 mg/L), respectively.
Four patients (1%) had baseline blood pathogens: there was
one case of methicillin-susceptible S. aureus in the moxiﬂoxacin
group and one case each of S. aureus (susceptibility not tested;
isolate destroyed during transport to the central laboratory),
Streptococcus parasanguis and Klebsiella oxytoca in the TZP–
AMC group.
The susceptibility of the baseline pathogens to moxiﬂoxacin,
TZP and AMC is shown in Table S1 (available as Supplementary
data at JAC Online).
Clinical efﬁcacy
Overall, clinical success at TOC was similar for moxiﬂoxacin and
TZP–AMC in the PP and ITT populations (P¼not signiﬁcant)
(Figure2).Moxiﬂoxacinwasnon-inferiortoTZP–AMCinbothpopu-
lations as the lower limit of the 95% CI was above 210%. The
highest cure rates by clinical category were seen in patients with
abscesses and wound infections (Table 4). No statistically signiﬁ-
cant differences in clinical success rates were seenbetweentreat-
ments when patients were stratiﬁed for severity by Wilson risk
class (Table S2, available as Supplementary data at JAC Online).
Cure rates decreased with increasing severity (P,0.001,
Cochran–Mantel–Haenszel test stratiﬁed by treatment group).
Overall, clinical cure rates were similar in patients with versus
without initial surgery (90.6% versus 90.0%) and no differences
were seen in the two treatment groups. Similar numbers of PP
patients in each treatment arm required additional surgery (i.e.
performed after 48 h of initiation of the study drug) during
therapy [moxiﬂoxacin: 60/361 (16.6%); TZP–AMC: 56/307
(18.2%)]. The most frequent surgical procedures included local
debridement [moxiﬂoxacin: 29/361 (8.0%); TZP–AMC: 24/307
(7.8%)], (primary) closure [moxiﬂoxacin: 24/361 (6.6%); TZP–
AMC: 20/307 (6.5%)] and amputation [moxiﬂoxacin: 9/361
(2.5%); TZP–AMC: 17/307 (5.5%)]. Additional amputations were
done in 8.2% (9/110) of moxiﬂoxacin- and 16.7% (16/96) of
TZP–AMC-treated patients with DFI, respectively. One PP TZP–
AMC patient with ischaemic ulcer also had an additional amputa-
tion. Avast majority of patients with additional surgery were con-
sidered as clinical failures. No major differences were observed
between treatment groups with regard to clinical cure rates of
aerobic (86.6% overall) versus anaerobic (91.5% overall) bacterial
infections. Clinical response rates were similar for patients with
monomicrobial [moxiﬂoxacin: 113/129 (87.6%); TZP–AMC:
Table 1. Patient demographics and baseline characteristics (ITT and PP populations)
Characteristic
ITT PP
moxiﬂoxacin (N¼426) TZP–AMC (N¼377) moxiﬂoxacin (N¼361) TZP–AMC (N¼307)
Sex, male, n (%) 267 (62.7) 255 (67.6) 229 (63.4) 213 (69.4)
Mean (SD) age, years 53.4 (16.2) 52.8 (16.0) 52.7 (16.4) 51.8 (15.9)
Mean (SD) body mass index, kg/m
2 28.2 (6.4) 27.0 (5.0) 27.8 (6.0) 27.0 (4.9)
Mean (range) temperature, 8C 39.2 (36.4–41.5) 39.2 (36.5–42.0) 39.2 (36.7–41.5) 39.2 (36.5–42.0)
Mean (SD) white blood cells, Giga/L 10.8 (4.8) 10.0 (3.9) 10.9 (4.8) 10.2 (3.9)
Mean (SD) HbA1c, % 7.3 (2.5) 7.0 (2.2) 7.4 (2.6) 7.0 (2.2)
Mean (SD) C-reactive protein, mg/L 9.0 (9.1) 8.7 (8.9) 9.0 (8.9) 8.9 (8.9)
Co-morbid condition, n (%)
cardiac 101 (23.7) 81 (21.5) 81 (22.4) 60 (19.5)
malignancy 7 (1.6) 6 (1.6) 5 (1.4) 4 (1.3)
diabetes mellitus 180 (42.3) 136 (36.1) 156 (43.2) 113 (36.8)
hepatic 7 (1.6) 13 (3.4) 6 (1.7) 9 (2.9)
renal 21 (4.9) 21 (5.6) 18 (5.0) 15 (4.9)
respiratory 21 (4.9) 23 (6.1) 17 (4.7) 18 (5.9)
transplantation 0 1 (0.3) 0 1 (0.3)
vascular 124 (29.1) 119 (31.6) 106 (29.4) 89 (29.0)
HbA1c, glycosylated haemoglobin.
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ITT PP
moxiﬂoxacin
(N¼426)
TZP–AMC
(N¼377)
moxiﬂoxacin
(N¼361)
TZP–AMC
(N¼307)
cSSSI diagnosis, n (%)
major abscess 183 (43.0) 169 (44.8) 167 (46.3) 153 (49.8)
diabetic foot infection 123 (28.9) 110 (29.2) 110 (30.5) 96 (31.3)
wound infection 72 (16.9) 55 (14.6) 62 (17.2) 47 (15.3)
infected ischaemic ulcer 24 (5.6) 18 (4.8) 22 (6.1) 11 (3.6)
other cSSSI 4 (0.9) 3 (0.8) — —
uSSSI or no infection 20 (4.7) 22 (5.8) — —
Source of infection
community acquired, n (%) 368 (86.4) 345 (91.5) 310 (85.9) 280 (91.2)
hospital acquired, n (%) 58 (13.6) 32 (8.5) 51 (14.1) 27 (8.8)
Location of primary lesion, n (%)
foot 154 (36.2) 132 (35.0) 134 (37.1) 110 (35.8)
legs 82 (19.2) 78 (20.7) 57 (15.8) 46 (15.0)
buttocks and genitals 58 (13.6) 61 (16.2) 53 (14.7) 55 (17.9)
arm 37 (8.7) 32 (8.5) 35 (9.7) 29 (9.4)
abdomen and groin 39 (9.2) 22 (5.8) 32 (8.9) 21 (6.8)
hand 20 (4.7) 20 (5.3) 19 (5.3) 19 (6.2)
head and neck 22 (5.2) 21 (5.6) 19 (5.3) 18 (5.9)
chest and back 14 (3.3) 11 (2.9) 12 (3.3) 9 (2.9)
Deepest plane involved, n (%)
fascia 153 (35.9) 145 (38.5) 125 (34.6) 115 (37.5)
muscle 117 (27.5) 101 (26.8) 97 (26.9) 79 (25.7)
fat 105 (24.6) 78 (20.7) 96 (26.6) 72 (23.5)
bone 20 (4.7) 26 (6.9) 18 (5.0) 21 (6.8)
dermis 17 (4.0) 14 (3.7) 14 (3.9) 8 (2.6)
other
a 14 (3.3) 13 (3.4) 11 (3.0) 12 (3.9)
Wilson score evaluation
b
mean (SD) score 83.5 (31.3) 81.4 (30.2) 84.7 (32.4) 83.3 (30.8)
risk class, n (%)
I 118 (27.7) 116 (30.8) 100 (27.7) 99 (32.2)
II 92 (21.6) 65 (17.2) 84 (23.2) 54 (17.6)
III 92 (21.6) 87 (23.1) 75 (20.8) 73 (23.8)
IV 124 (29.1) 109 (28.9) 102 (28.3) 81 (26.4)
White blood cells ≥10500 Giga/L, n (%) 174 (40.8) 111 (29.4) 149 (41.3) 97 (31.6)
C-reactive protein ≥0.5 mg/dL, n (%) 378 (88.7) 334 (88.6) 328 (90.9) 277 (90.2)
Temperature .388C, n (%) 385 (90.4) 335 (88.9) 329 (91.1) 279 (90.9)
Initial
c surgery, n (%) 321 (75.4) 298 (79.0) 285 (78.9) 256 (83.4)
Mean (SD) duration of anaesthesia (min) 43.1 (48.9) 38.8 (35.7) 42.8 (49.1) 37.6 (33.8)
Most common initial surgeries
c,d, n (%)
local debridement 99 (23.2) 85 (22.5) 87 (24.1) 72 (23.5)
abscess drainage 237 (55.6) 222 (58.9) 212 (58.7) 199 (64.8)
extensive debridement 113 (26.5) 112 (29.7) 97 (26.9) 99 (32.2)
amputation 58 (13.6) 48 (12.7) 53 (14.7) 36 (11.7)
Other cSSSIs in the moxiﬂoxacin group were complicated erysipelas (n¼1), necrotizing fasciitis (n¼2) and other skin infection requiring surgery
(n¼1), and in the comparator group were necrotizing fasciitis (n¼2) and other skin infection requiring surgery (n¼1).
aTendon, articulum/joint, aponeurosis and subcutaneous tissue.
bSee reference 19.
cBefore or within 48 h of initiation of study drug.
dPatients may have undergone more than one type of surgery.
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JAC120/131 (91.6%)] or polymicrobial [moxiﬂoxacin: 120/139
(86.3%); TZP–AMC: 95/112 (84.8%)] infections.
There were no major differences between the treatment
groups regarding the types of patients assessed as clinical fail-
ures at TOC. Most were male, assigned to Wilson risk class IV,
with a primary diagnosis of DFI and the deepest tissue involved
was most frequently the muscle or fascia. Most had undergone
surgical intervention, mainly abscess drainage, amputation, or
local or extensive debridement. The most frequent baseline
pathogen observed for these patients was methicillin-susceptible
S. aureus, consistent with the main analysis populations. This
pathogen was, however, eradicated from most clinical failures
by the EOT or TOC visit.
Bacteriological efﬁcacy
Overall, the bacteriological efﬁcacy was high in both treatment
arms. In the MBV population, moxiﬂoxacin was non-inferior to
TZP–AMC with respect to bacteriological efﬁcacy at TOC
(Table 3). These results are supported by those of the ITT popu-
lation (data not shown). The bacteriological efﬁcacy against the
most commonly isolated organisms was similar between treat-
ment arms (Table 3). Although MRSA infection was identiﬁed in
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Figure 2. Clinical success at TOC (PP and ITT populations).
Table 3. Commonly occurring baseline causative organisms (isolated in ≥1% of patients in either treatment group) from skin and skin structures,
and bacteriological success (eradication and presumed eradication) rates by pathogen at TOC (MBV population)
Causative organisms at baseline, n (%) Bacteriological success rate, n/N (%)
moxiﬂoxacin TZP–AMC moxiﬂoxacin TZP–AMC
Total causative organisms 497 429 432/497 (86.9) 370/429 (86.2)
Gram-positive aerobic cocci 320 (64.4) 280 (65.3) 276/320 (86.3) 240/280 (85.7)
Staphylococcus aureus
methicillin-susceptible 152 (30.6) 154 (35.9) 134/152 (88.2) 134/154 (87.0)
methicillin-resistant 23 (4.6) 17 (4.0) 17/23 (73.9) 15/17 (88.2)
Enterococcus faecalis 61 (12.3) 50 (11.7) 48/61 (78.7) 39/50 (78.0)
Streptococcus pyogenes 36 (7.2) 24 (5.6) 34/36 (94.4) 22/24 (91.7)
Streptococcus agalactiae 31 (6.2) 13 (3.0) 26/31 (83.9) 12/13 (92.3)
Streptococcus equisimilis 13 (2.6) 12 (2.8) 12/13 (92.3) 10/12 (83.3)
Gram-negative aerobic bacilli 142 (28.6) 119 (27.7) 123/142 (86.6) 103/119 (86.6)
Escherichia coli
a 58 (11.7) 55 (12.8) 52/58 (89.7) 49/55 (89.1)
Enterobacter cloacae
a 22 (4.4) 19 (4.4) 21/22 (95.5) 19/19 (100.0)
Klebsiella pneumoniae
a 14 (2.8) 9 (2.1) 9/14 (64.3) 5/9 (55.6)
Proteus mirabilis
a 8 (1.6) 9 (2.1) 7/8 (87.5) 7/9 (77.8)
Acinetobacter baumannii 11 (2.2) 5 (1.2) 10/11 (90.9) 5/5 (100.0)
Klebsiella oxytoca
a 7 (1.4) 6 (1.4) 7/7 (100.0) 6/6 (100.0)
Pseudomonas aeruginosa 9 (1.8) 4 (0.9) 8/9 (88.9) 2/4 (50.0)
Morganella morganii
a 6 (1.2) 4 (0.9) 3/6 (50.0) 4/4 (100.0)
Proteus vulgaris 3 (0.6) 6 (1.4) 3/3 (100.0) 4/6 (66.7)
Anaerobes 35 (7.0) 30 (7.0) 33/35 (94.3) 27/30 (90.0)
Bacteroides fragilis 26 (5.2) 19 (4.4) 24/26 (92.3) 16/19 (84.2)
n/N¼number of bacteriological successes/number of organisms isolated.
aData shown are for extended-spectrum b-lactamase (ESBL) and non-ESBL producers. The following numbers of ESBL producers were isolated for
each species (moxiﬂoxacin and TZP–AMC, respectively): E. coli,4( ,1%) and 1 (,1%); E. cloacae, 17 (3%) and 14 (3%); K. pneumoniae,4( ,1%)
and 4 (,1%); and P. mirabilis, 8 (2%) and 7 (2%).
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infection, n¼5; and infected ischaemic ulcer, n¼5), the overall
bacterial success rates for moxiﬂoxacin and TZP–AMC against
this pathogen were high [17/23 (73.9%) and 15/17 (88.2%),
respectively]. No moxiﬂoxacin-treated and one TZP–AMC-treated
patient received concomitant anti-MRSA treatment.
Safety
Both treatment regimens were well tolerated (Table 5), with a
total of 100/426 (23.5%) moxiﬂoxacin- and 72/377 (19.1%)
TZP–AMC-treated patients experiencing a treatment-emergent
AE (P¼0.14). The incidence of drug-related AEs was similar in
each group [moxiﬂoxacin: 37/426 (8.7%) versus TZP–AMC:
28/377 (7.4%); P¼0.60], with the most commonly occurring
drug-related AE in both arms being diarrhoea (Table 5). Tests
for C. difﬁcile in patients with conﬁrmed diarrhoea indicated
that three moxiﬂoxacin- and one TZP–AMC-treated patient
had C. difﬁcile isolated or the C. difﬁcile toxin detected. Withdra-
wal rates due to drug-related AEs were low in both arms [moxi-
ﬂoxacin: n¼8 (1.9%) versus TZP–AMC: n¼3 (0.8%); P¼0.23]. All
events in each arm resolved. A serious AE was reported in 21
(4.9%) patients in the moxiﬂoxacin group and 14 (3.7%)
patients in the TZP–AMC group (P¼0.49). These events were
considered to be drug related in six patients. Serious
drug-related AEs in the moxiﬂoxacin arm were prolonged QT
interval (n¼2), increased blood alkaline phosphatase (n¼1)
and wound infection (n¼1). In the TZP–AMC group, serious
AEs were impaired healing (n¼1) and wound infection (n¼1).
Four deaths occurred, none of which was considered to be
drug related: deaths in the moxiﬂoxacin group (n¼3) were
due to cardiopulmonary failure, renal failure and shock, and pul-
monary embolism; the death in the TZP–AMC group (n¼1) was
due to pulmonary embolism.
Table 4. Clinical success at TOC by diagnosis (PP and ITT populations), as assessed by the DRC
Clinical cure, n/N (%)
PP ITT
moxiﬂoxacin
(N¼361)
TZP–AMC
(N¼307) estimate: 95% CI
moxiﬂoxacin
(N¼426)
TZP–AMC
(N¼377) estimate: 95% CI
All patients 320/361 (88.6) 275/307 (89.6) 20.72: 25.3, 3.9 350/426 (82.2) 305/377 (80.9) 1.25: 23.8, 6.3
Diagnosis
major abscess 160/167 (95.8) 147/153 (96.1) 0.2: 24.2, 4.5 163/183 (89.1) 151/169 (89.3) 0.8: 25.6, 7.2
diabetic foot infection 84/110 (76.4) 75/96 (78.1) 22.8: 214.5, 9.0 86/123 (69.9) 76/110 (69.1) 20.1: 212.4, 12.1
wound infection 59/62 (95.2) 45/47 (95.7) 21.4: 29.7, 6.8 65/72 (90.3) 48/55 (87.3) 2.3: 28.6, 13.2
infected ischaemic ulcer 17/22 (77.3) 8/11 (72.7) 6.2: 227.2, 39.6 17/24 (70.8) 9/18 (50.0) 20.1: 29.0, 49.2
n/N, number of patients experiencing clinical cure/number of patients with a given diagnosis.
Table 5. Incidence of treatment-emergent AEs (ITT/safety population)
Moxiﬂoxacin (N¼426), n (%) TZP–AMC (N¼377), n (%) P value
Any treatment-emergent AE 100 (23.5) 72 (19.1) 0.14
Any treatment-emergent drug-related AEs
a 37 (8.7) 28 (7.4) 0.60
ventricular extrasystoles 0 2 (0.5) —
upper abdominal pain 0 2 (0.5) —
diarrhoea 8 (1.9) 4 (1.1) —
ﬂatulence 0 2 (0.5) —
nausea 3 (0.7) 2 (0.5) —
vomiting 1 (0.2) 2 (0.5) —
Withdrawal due to treatment-emergent drug-related AE
b 8 (1.9) 3 (0.8) 0.23
Any treatment-emergent serious AE 21 (4.9) 14 (3.7) 0.49
Any treatment-emergent drug-related serious AE 4 (0.9) 2 (0.5) 0.69
aIndividual events listed under treatment-emergent drug-related AEs occurring in ≥0.5% of patients in either treatment group.
bAEs leading to withdrawal, moxiﬂoxacin: cytolytic hepatitis (n¼1); drug hypersensitivity (n¼1); QT prolongation (n¼2); increase in blood alkaline
phosphatase (n¼1); gout (n¼1); dizziness (n¼1); and allergic dermatitis (n¼1). TZP–AMC: diarrhoea (n¼1); wound re-infection (n¼1); and allergic
dermatitis (n¼1).
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In this comparative, randomized, double-blind, multicentre
study, moxiﬂoxacin iv/oral was non-inferior to TZP–AMC in the
treatment of cSSSIs, stratiﬁed according to severity and the
need for initial baseline surgery. Such stratiﬁcation prior to ran-
domization has not, to the authors’ knowledge, been carried
out in other clinical trials and its omission from cSSSI studies
has been identiﬁed as a potential design ﬂaw.
24 The four infec-
tions that determined eligibility were clearly deﬁned: major
abscess; DFI; wound infection; and infected ischaemic ulcer.
DFI was assessed using several severity scores (data not
shown) to ensure that patients with moderate-to-severe infec-
tions were recruited. The characteristics of the subgroup of
patients with abscesses reﬂected that of a population with
major abscesses, based on the size and location of abscesses
seen. Such patients have been identiﬁed as potentially beneﬁting
from hospital admission and initial iv therapy in addition to sur-
gical intervention, especially if diabetes is a co-morbidity.
6 The
strict methodology used provided an in-depth and accurate
assessment of patients and disease characteristics. Assessment
by a blinded DRC, prospective use of the Wilson risk class and
standardized photographic assessment of the lesions all helped
eliminate investigator bias. The use of repeated photographs as
a diagnostic tool has been validated in other clinical specialties,
e.g. dermatology,
25 and was used in the current study to
improve diagnostic consistency.
24 Indeed, a recent
meta-analysis of cSSSI trials
24 concluded that the legitimacy of
using antimicrobials could be conﬁrmed by such an approach.
Retrospective stratiﬁcation by cSSSI subgroup is common in clini-
cal trials, but prospective stratiﬁcation by disease type and sever-
ity, and detailed assessments of patients’ wound types and
clinical responses have not, to our knowledge, been reported in
other cSSSI studies. Therefore, the RELIEF study adds a unique
dimension to similar studies in this area and overcomes many
shortcomings of previous trials.
24
Moxiﬂoxacin was shown to be clinically non-inferior to TZP–
AMC. Thus, the current data conﬁrm those from previous studies
of cSSSIs.
3,18,26 As well as good overall efﬁcacy, moxiﬂoxacin had
comparable efﬁcacy to TZP–AMC in the different subgroups of
cSSSI, with particularly good efﬁcacy in patients with abscesses.
Cure rates were lower in patients with compromised vascular per-
fusion (DFI and ischaemic ulcers); however, the results in patients
with a DFI are similar to those seen in other trials of antimicrobial
treatments in cSSSIs.
26 The analysis was not powered to look at
differences in clinical efﬁcacy in subgroups.
The type and distribution of baseline pathogens was as
expected from previous studies, with the most commonly occur-
ring pathogens being Gram-positive aerobes (in  65% of PP
patients), particularly methicillin-susceptible S. aureus,
b-haemolytic streptococci and E. faecalis. The majority of the E.
faecalis strains were isolated from DFIs (n¼59) and abscesses
(n¼24). E. faecalis is known to be commonly isolated from
patients with a DFI, though it is not clear whether this is contami-
nation or colonization of the site. As in the present trial, previous
studies have shown good clinical outcomes despite the use of
agents that are not active against enterococci.
27,28Fewanaerobic
pathogens were isolated; it is possible these have a more impor-
tant causative role to play in severe infections, such as necrotizing
fasciitis.
1However,becausethiswasalargemultinationalstudy,it
isalsopossiblethatdespiteoptimaltransportcontainersandcon-
ditions, anaerobes did not survive the journey to the central lab-
oratory as well as aerobes did. High bacteriological success rates
were achieved in both arms, and success rates were generally
similar between mono- and polymicrobial infections, as would
be expected when using two broad-spectrum antibiotics. MRSA
isolates were isolated relatively infrequently from patients with
DFIsinthis study(12.4%), althoughpreviousstudieshaveisolated
MRSAfrom30%–50%ofsuchinfections.
29–31Thereasonsforthis
areunclear,butmayberelatedtotheexclusioncriteriaand/ordif-
fering epidemiology and geographical location of various study
populations. Recent work has shown that across Europe, isolation
rates of MRSA from cSSSIs can vary from 3% to 48%.
32 Nonethe-
less, success rates against MRSA were similar and relatively good
inbotharms.Asneitherofthetreatmentregimenswasspeciﬁcally
used for anti-MRSA activity, this clearance may be because the
isolate was a colonizer rather than a pathogen or due to the role
of extensive debridement; this is particularly likely in patients
who received no anti-MRSA therapy but still experienced clinical
cure. Given the limited activity of moxiﬂoxacin and lack of activity
of TZP–AMC against community-acquired MRSA (CA-MRSA),
patients with known MRSA infections should not be treated with
these regimens, despite the in vitro susceptibility of some isolates
tomoxiﬂoxacin.IncontrasttotheUSA,theprevalenceofCA-MRSA
remains relatively low (1%–3%) in most European countries.
33
Safety data are comparable to those from previous clinical
trials of moxiﬂoxacin,
34 which can be considered safe and well
tolerated in the patient population enrolled to the study. Speciﬁ-
cally, similar numbers and types of AEs were seen in each treat-
ment arm and no cardiac events that could be surrogates of
arrhythmia occurred. C. difﬁcile-associated diarrhoea rates were
notably low in the current study. The literature suggests that
almost all classes of antibiotics may drive the selection of resist-
ant strains of C. difﬁcile that can cause C. difﬁcile-associated
diarrhoea outbreaks if infection control practices fail.
35 Fluoroqui-
nolones are probably not different in this respect from other
classes of antibiotics.
36 It is clear, however, that irrespective of
the antibiotic being used, good antibiotic stewardship and scru-
pulous hygiene are key to limiting C. difﬁcile-associated diarrhoea
and should be exercised in all clinical situations.
37
Possible weaknesses of the study include the limited analysis
of microorganisms; this could lead to underestimation of the
polymicrobial character of the cSSSIs. Citron et al.
38 commented
on the large number and variety of organisms that were isolated
from specimens in patients with moderate-to-severe DFIs, and
found that most patients had polymicrobial cultures. However,
the contribution to the pathogenicity of many of the micro-
organisms isolated from open lesions is still unclear.
While surgical intervention and/or drainage are clinically
important features of cSSSI management,
1,4 it is unclear how
they may affect outcomes in antibiotic trials. Although only
patients with residual infection after surgery were included, the
role of antibiotic therapy after surgery is more difﬁcult to
assess and this may work in favour of equivalence or non-
inferiority. The current study did, however, stratify for surgical
intervention in order to reduce any confounding effects.
Most patients in this study were recruited from Eastern
Europe, despite concerted efforts to recruit from Western
Europe, which raises the question of whether the data are appli-
cable across geographical populations. Differences may exist
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isolated, the severity of infections treated or referred to hospital,
patients’ access to healthcare and possible variation in the
accepted standards of surgical care. However, these differences
are speculative and their impact is unknown. A review of the
2008 report of the European Antibiotic Resistance Surveillance
System
39 suggests that differences tend to be between Southern
and Northern Europe (particularly in the incidence of MRSA)
rather than between Western and Eastern Europe.
Conclusions
Once-daily iv/oral moxiﬂoxacin monotherapy was clinically and
bacteriologically non-inferior to a commonly used broad-
spectrum antibiotic therapy (4.0/0.5 g of piperacillin/tazobactam
iv thrice daily followed by 875/125 mg of oral amoxicillin/clavu-
lanate twice daily) in patients with cSSSIs, across the range of
infection severities included in this study. Moxiﬂoxacin sequential
monotherapy, together with surgery, is an appropriate option for
patients with cSSSIs, including those with polymicrobial infec-
tions, when used in accordance with the prescribing guidelines.
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